WWM
VKTX icon

Wolff Wiese Magana’s Viking Therapeutics VKTX Stock Holding History

Wolff Wiese Magana’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-70
Closed -$2.46K – 1025
2025
Q4 		$2.46K Hold
70
– – ﹤0.01% 719
2025
Q3 		$1.84K Hold
70
– – ﹤0.01% 770
2025
Q2 		$1.85K Hold
70
– – ﹤0.01% 740
2025
Q1 		$1.69K Sell
70
-1,792
-96% -$56.6K ﹤0.01% 757
2024
Q4 		$74.9K Buy
+1,862
New +$106K 0.05% 157

Other funds holding VKTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Wolff Wiese Magana's VKTX Position: Q1 2026 in Review

Wolff Wiese Magana sold out of Viking Therapeutics (VKTX) in Q1 2026, closing a stake of 70 shares — an estimated $2.46K sold.

Wolff Wiese Magana first reported a position in VKTX in Q4 2024 and held it in 5 quarters. The position peaked at $74.9K in Q4 2024. 413 funds tracked by Wall St. Rank hold VKTX as of Q1 2026.

  • Wolff Wiese Magana reported no remaining Viking Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Wolff Wiese Magana sold 70 Viking Therapeutics shares in Q1 2026, an estimated $2.46K.
  • Wolff Wiese Magana first reported a position in Viking Therapeutics in Q4 2024 and held it in 5 quarters.
  • Wolff Wiese Magana's Viking Therapeutics position peaked at $74.9K in Q4 2024.
  • 413 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2026.

Based on Wolff Wiese Magana's 13F filing for Q1 2026, filed 13 Apr 2026.